{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:30:05Z","timestamp":1790188205311,"version":"4.1.0"},"reference-count":50,"publisher":"Europa Digital & Publishing","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["EuroIntervention"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.4244\/eijv9i11a224","type":"journal-article","created":{"date-parts":[[2014,4,23]],"date-time":"2014-04-23T08:22:34Z","timestamp":1398241354000},"page":"1333-1341","source":"Crossref","is-referenced-by-count":8,"title":["Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis"],"prefix":"10.4244","volume":"9","author":[{"given":"Jean-Pierre","family":"Bassand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2774","reference":[{"key":"key-2014416142221-0","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.","volume":"308","author":"Antiplatelet Trialists\u2019 Collaboration.","year":"1994","journal-title":"BMJ."},{"key":"key-2014416142221-1","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.","volume":"345","author":"Yusuf S","year":"2001","journal-title":"N Engl J Med."},{"key":"key-2014416142221-2","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","article-title":"ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).","volume":"32","author":"Hamm CW","year":"2011","journal-title":"Eur Heart J."},{"key":"key-2014416142221-3","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742cf6","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines.","volume":"127","author":"O\u2019Gara PT.","year":"2013","journal-title":"Circulation."},{"key":"key-2014416142221-4","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC).","volume":"33","author":"Steg PG","year":"2012","journal-title":"Eur Heart J."},{"key":"key-2014416142221-5","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1161\/CIR.0b013e318256f1e0","article-title":"2012 ACCF\/AHA focused update of the guideline for the management of patients with unstable angina\/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines.","volume":"126","author":"Jneid H","year":"2012","journal-title":"Circulation."},{"key":"key-2014416142221-6","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1093\/eurheartj\/ehq326","article-title":"Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study).","volume":"31","author":"Fox KA","year":"2010","journal-title":"Eur Heart J."},{"key":"key-2014416142221-7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1161\/01.CIR.97.1.26","article-title":"Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis.","volume":"97","author":"Van Belle E.","year":"1998","journal-title":"Circulation."},{"key":"key-2014416142221-8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/00001573-200211000-00009","article-title":"Angioscopy and ischemic heart disease.","volume":"17","author":"Saltzman AJ","year":"2002","journal-title":"Curr Opin Cardiol."},{"key":"key-2014416142221-9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.thromres.2011.03.011","article-title":"Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome?","volume":"128","author":"Skeppholm M","year":"2011","journal-title":"Thromb Res."},{"key":"key-2014416142221-10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/01.CIR.90.1.61","article-title":"Persistent activation of coagulation mechanism in unstable angina and myocardial infarction.","volume":"90","author":"Merlini PA","year":"1994","journal-title":"Circulation."},{"key":"key-2014416142221-11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1023\/A:1008895827320","article-title":"The TIMI 9b and GUSTO IIb trials and the \u201cthrombin hypothesis\u201d.","volume":"4","author":"Andreotti F.","year":"1997","journal-title":"J Thromb Thrombolysis."},{"key":"key-2014416142221-12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1023\/A:1008828812299","article-title":"Thrombin Hypothesis: The TIMI 9B and GUSTO IIB Trials Have Successfully Disproven\/Proven the Thrombin Hypothesis.","volume":"4","author":"White HD.","year":"1997","journal-title":"J Thromb Thrombolysis."},{"key":"key-2014416142221-13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.amjmed.2009.09.001","article-title":"The thrombin hypothesis in ACS: a disappointing disconnect between bench data and bedside clinical trials.","volume":"123","author":"Cohen M.","year":"2010","journal-title":"Am J Med."},{"key":"key-2014416142221-14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1172\/JCI114723","article-title":"Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.","volume":"86","author":"Weitz JI","year":"1990","journal-title":"J Clin Invest."},{"key":"key-2014416142221-15","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1056\/NEJM199609123351103","article-title":"A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators.","volume":"335","year":"1996","journal-title":"N Engl J Med."},{"key":"key-2014416142221-16","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1161\/01.CIR.94.5.911","article-title":"Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial.","volume":"94","author":"Antman EM.","year":"1996","journal-title":"Circulation."},{"key":"key-2014416142221-17","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1161\/01.CIR.93.5.870","article-title":"Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial.","volume":"93","author":"Granger CB","year":"1996","journal-title":"Circulation."},{"key":"key-2014416142221-18","doi-asserted-by":"publisher","first-page":"8S","DOI":"10.1378\/chest.119.1_suppl.8S","article-title":"Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.","volume":"119","author":"Hirsh J","year":"2001","journal-title":"Chest."},{"key":"key-2014416142221-19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0140-6736(97)01180-X","article-title":"Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction.","volume":"350","author":"Coumadin Aspirin Reinfarction Study (CARS) Investigators.","year":"1997","journal-title":"Lancet."},{"key":"key-2014416142221-20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1161\/hc0502.103329","article-title":"Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study.","volume":"105","author":"Fiore LD","year":"2002","journal-title":"Circulation."},{"key":"key-2014416142221-21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1161\/01.CIR.0000024408.81821.32","article-title":"Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial.","volume":"106","author":"Brouwer MA","year":"2002","journal-title":"Circulation."},{"key":"key-2014416142221-22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0140-6736(02)09409-6","article-title":"Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial.","volume":"360","author":"van Es RF.","year":"2002","journal-title":"Lancet."},{"key":"key-2014416142221-23","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction.","volume":"347","author":"Hurlen M","year":"2002","journal-title":"N Engl J Med."},{"key":"key-2014416142221-24","first-page":"105:1270","article-title":"Oral anticoagulation for acute coronary syndromes.","volume":"19","author":"Brouwer MA","year":"2002","journal-title":"Circulation."},{"key":"key-2014416142221-25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","article-title":"Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit.","volume":"143","author":"Rothberg MB","year":"2005","journal-title":"Ann Intern Med."},{"key":"key-2014416142221-26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","article-title":"Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients.","volume":"27","author":"Andreotti F","year":"2006","journal-title":"Eur Heart J."},{"key":"key-2014416142221-27","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","article-title":"Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.","volume":"362","author":"Wallentin L","year":"2003","journal-title":"Lancet."},{"key":"key-2014416142221-28","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1111\/j.1538-7836.2005.01557.x","article-title":"Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction.","volume":"3","author":"Christersson C","year":"2005","journal-title":"J Thromb Haemost."},{"key":"key-2014416142221-29","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.","volume":"32","author":"Oldgren J","year":"2011","journal-title":"Eur Heart J."},{"key":"key-2014416142221-30","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.","volume":"119","author":"Alexander JH","year":"2009","journal-title":"Circulation."},{"key":"key-2014416142221-31","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome.","volume":"365","author":"Alexander JH","year":"2011","journal-title":"N Engl J Med."},{"key":"key-2014416142221-32","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1517\/13543784.2012.689286","article-title":"Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban.","volume":"21","author":"Apostolakis S","year":"2012","journal-title":"Expert Opin Investig Drugs."},{"key":"key-2014416142221-33","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1093\/eurheartj\/ehr334","article-title":"RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.","volume":"32","author":"Steg PG","year":"2011","journal-title":"Eur Heart J."},{"key":"key-2014416142221-34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.","volume":"374","author":"Mega JL","year":"2009","journal-title":"Lancet."},{"key":"key-2014416142221-35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome.","volume":"366","author":"Mega JL","year":"2012","journal-title":"N Engl J Med."},{"key":"key-2014416142221-36","article-title":"Bayer\u2019s Xarelto\u00ae approved in the EU for secondary prevention after an acute coronary syndrome. 2013.","author":"Bayer HealthCare AG.","journal-title":"Available at: http:\/\/press.healthcare.bayer.com\/en\/press\/news-details-page.php\/15050\/2013-0292."},{"key":"key-2014416142221-37","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes.","volume":"357","author":"Wiviott SD","year":"2007","journal-title":"N Engl J Med."},{"key":"key-2014416142221-38","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.","volume":"364","author":"Diener HC","year":"2004","journal-title":"Lancet."},{"key":"key-2014416142221-39","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.jacc.2012.02.008","article-title":"New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.","volume":"59","author":"De Caterina R.","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"key-2014416142221-40","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation.","volume":"365","author":"Granger CB","year":"2011","journal-title":"N Engl J Med."},{"key":"key-2014416142221-41","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation.","volume":"364","author":"Connolly SJ","year":"2011","journal-title":"N Engl J Med."},{"key":"key-2014416142221-42","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.","volume":"365","author":"Patel MR","year":"2011","journal-title":"N Engl J Med."},{"key":"key-2014416142221-43","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/378337a0","article-title":"Blood coagulation. The thrombin paradox.","volume":"378","author":"Griffin JH.","year":"1995","journal-title":"Nature."},{"key":"key-2014416142221-44","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1182\/blood-2002-03-0954","article-title":"Coagulation activation and long-term outcome in acute coronary syndromes.","volume":"102","author":"Ardissino D","year":"2003","journal-title":"Blood."},{"key":"key-2014416142221-45","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/j.jacc.2004.02.051","article-title":"A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study.","volume":"43","author":"Simoons ML","year":"2004","journal-title":"J Am Coll Cardiol."},{"key":"key-2014416142221-46","article-title":"A Study Exploring Two Strategies of Rivaroxaban and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention (PIONEER AF-PCI). 2013.","author":"ClinicalTrials.gov.","journal-title":"Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01830543."},{"key":"key-2014416142221-47","article-title":"Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS). 2013.","author":"ClinicalTrials.gov.","journal-title":"Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01776424."},{"key":"key-2014416142221-48","article-title":"New pivotal phase III study initiated with Bayer\u2019s Xarelto\u00ae (rivaroxaban) in patients with chronic heart failure and significant coronary artery disease. 2013.","author":"Bayer HealthCare AG.","journal-title":"Available at: http:\/\/press.healthcare.bayer.com\/en\/press\/news-details-page.php\/14944\/2013-0166."},{"key":"key-2014416142221-49","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1161\/01.CIR.103.18.2310","article-title":"The search for replacements for unfractionated heparin.","volume":"103","author":"Antman EM.","year":"2001","journal-title":"Circulation."}],"container-title":["EuroIntervention"],"original-title":[],"deposited":{"date-parts":[[2014,4,23]],"date-time":"2014-04-23T08:23:02Z","timestamp":1398241382000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.pcronline.com\/eurointervention\/70th_issue\/224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["EIJV9I11A224"],"URL":"https:\/\/doi.org\/10.4244\/eijv9i11a224","relation":{},"ISSN":["1774-024X"],"issn-type":[{"value":"1774-024X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}